Cancer is the leading cause of death in the world with over 20 million new cases diagnosed annually. Sixty percent of these cases are treatable via current conventional therapies, while the other forty percent are presently not completely treatable. Our “Universal off-the-shelf allogeneic T cell therapy” is a novel treatment and it can meet these unmet medical needs. The treatment can treat many patients who do not have effective therapies.